Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: CTRVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Hepion Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Hepion Pharmaceuticals's regulatory disclosures and financial reporting.
Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals, Inc. director and Chief Executive Officer Gary S. Stetz filed an initial statement of beneficial ownership on Form 3. The filing lists him as both a director and officer of the company but does not report any specific holdings or transactions in this excerpt.
Hepion Pharmaceuticals, Inc. filed an initial Form 3 identifying Vincent S. LoPriore as an insider. He is listed as both a director and an officer, serving as Executive Chairman. The filing does not report any share purchases, sales, or other insider transactions.
Hepion Pharmaceuticals, Inc. filed an initial ownership report for director Appajosyula Sireesh on Form 3. The filing shows no reportable transactions and no derivative positions, with all buy, sell, acquire, and dispose counts and related share amounts reported as zero.
Hepion Pharmaceuticals announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons, effective immediately on March 16, 2026. The Board moved quickly to reconfigure leadership, naming Gary Stetz as interim CEO and a director the same day.
The Board also appointed Vincent LoPriore as Executive Chairman and added Sireesh Appajosyula and Chase LoPriore as directors. The company states there are no special arrangements behind these appointments and no family relationships between the new leaders and existing directors or executive officers.